Frontiers in Medicinal Chemistry

Volume 7

by

Atta-ur-Rahman , M. Iqbal Choudhary , Jizhou Wang, Allen B. Reitz

DOI: 10.2174/97816080597061150701
eISBN: 978-1-60805-970-6, 2015
ISBN: 978-1-60805-971-3
ISSN: 1567-2042 (Print)
ISSN: 1875-5763 (Online)



Indexed in: Book Citation Index, Science (BKCI-S), Web of Science, BIOSIS Previews, EMBASE, Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

“Frontiers in Medicinal Chemistry” is an Ebook series devoted to the review of ...[view complete introduction]
US $
Buy Personal eBook
190
Order Library eBook
760
Order Printed Copy
*190
Order PDF + Printed Copy (Special Offer)
*285

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Also available:
Download Flyer

Antioxidants and Neuroprotection in the Brain and Retina

- Pp. 3-33 (31)

Charanjit Kaur, Gurugirijha Rathnasamy and Eng-Ang Ling

Abstract

Oxidative stress is implicated in the pathogenesis of a number of neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis and stroke in the adult as well as in conditions such as periventricular white matter damage in the neonatal brain. It has also been linked to the disruption of blood brain barrier (BBB) in hypoxic-ischemic injury. Both experimental and clinical results have shown that antioxidants such as melatonin, a neurohormone synthesized and secreted by the pineal gland and edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a newly developed drug, are effective in reducing oxidative stress and are promising neuroprotectants in reducing brain damage. Indeed, the neuroprotective effects of melatonin in many central nervous system (CNS) disease conditions such as amyotrophic lateral sclerosis, PD, AD, ischemic injury, neuropsychiatric disorders and head injury are well documented. Melatonin affords protection to the BBB in hypoxic conditions by suppressing the production of vascular endothelial growth factor and nitric oxide which are known to increase vascular permeability. The protective effects of melatonin against hypoxic damage have also been demonstrated in newborn animals whereby it attenuated damage in different areas of the brain. Furthermore, exogenous administration of melatonin in newborn animals effectively enhanced the surface receptors and antigens on the macrophages/microglia in the CNS indicating its immunoregulatory actions. Not only did melatonin prevent neuronal loss in the brain, but also protected the retinal neurons in ocular diseases such as glaucoma, diabetic retinopathy and age related macular degeneration. Another anti-oxidant, edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult. It can counteract toxicity from activated microglia. This review summarizes the clinical and experimental data highlighting the therapeutic potential of melatonin and edaravone in neuroprotection in various disorders of the CNS.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science